Boehringer puts a target on Humira, says pushing it off formularies is necessary
For biosimilars to win, AbbVie has to lose, according to Boehringer Ingelheim.
The German drugmaker on Wednesday said that its goal of getting more uptake …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
